Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 65Years
All Genders
Healthy Volunteers
NCT07317544

Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Healthy Adults With and Without Androgenetic Alopecia

Led by Absci Pty Ltd. · Updated on 2026-05-08

227

Participants Needed

4

Research Sites

134 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to learn if ABS-201 (a new medication) is safe and tolerable when used to improve hair growth in men and women. The trial will start with healthy volunteers and if safe, will treat participants with certain types of hair loss. The main questions it aims to answer are: What medical problems, if any, do participants experience when taking a single dose or many doses of ABS-201? How does the medication, ABS-201, compare to placebo (a look alike substance that does not contain any medication). Participants who qualify for the trial will receive either ABS-201 or a placebo, and visit the study clinic for scheduled checkups and tests for approximately 1 year.

CONDITIONS

Official Title

Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Healthy Adults With and Without Androgenetic Alopecia

Who Can Participate

Age: 18Years - 65Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants must be overtly healthy based on medical evaluation including history, physical exam, and ECG
  • Normal hematology, clinical chemistry, coagulation tests, and urine analysis
  • Body mass index (BMI) between 18 and 32 kg/m2, and total body weight over 60 kg
  • Male and female participants must agree to avoid pregnancy during the trial
  • Must be able to give signed informed consent
  • No signs or symptoms of active or latent tuberculosis
  • For androgenetic alopecia patients: diagnosis with Norwood-Hamilton Scale III vertex to V pattern
  • Willing to clip target hair area for analysis and avoid scalp pigmentation products
  • Willing to keep approximately the same hair length at each study visit
  • For postmenopausal women with androgenetic alopecia: diagnosis with Ludwig Scale I-3, I-4, II-1, II-2 pattern and history of androgenetic alopecia for at least 12 months without rapid progression in the prior 6 months
Not Eligible

You will not qualify if you...

  • History or presence of cancer except basal cell carcinoma or cervical dysplasia successfully treated with no recurrence for 90 days before screening
  • History of liver disease, Gilbert's syndrome, or abnormal liver function tests at screening
  • Abnormal blood pressure or pulse rate outside specified ranges
  • Positive test for HIV, hepatitis B, or hepatitis C
  • Recent blood donation
  • Any clinically significant psychiatric disorder
  • Pregnant, breastfeeding, or planning pregnancy during the study
  • History of postpartum depression, perimenopausal mood instability, or estrogen withdrawal syndrome
  • For androgenetic alopecia participants: prior use of topical minoxidil within 3 months, oral minoxidil or other hair growth stimulators within 6 months, finasteride within 6 months, or dutasteride within 12 months before screening
  • Use of GLP-1 receptor agonists within 3 months before screening
  • History of hair transplantation or major scalp procedures, or plans for such during the study
  • Use of hair extensions, wigs, hairpieces, weaves, or other artificial hair enhancements within 30 days before screening and throughout the study
  • History of significant scalp dermatologic diseases that could interfere with hair assessments or imaging

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Momentum Darlinghurst

Sydney, New South Wales, Australia, 2010

Actively Recruiting

2

Nucleus Network Brisbane

Brisbane, Queensland, Australia, 4006

Actively Recruiting

3

Sinclair Dermatology

Melbourne, Victoria, Australia, 3002

Not Yet Recruiting

4

Nucleus Network

Melbourne, Victoria, Australia, 3004

Actively Recruiting

Loading map...

Research Team

C

Charles Romano, MPH

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

7

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here